DiaMedica Therapeutics: Pay

DiaMedica Therapeutics paid its 3 named executives $5.7M in total in FY2025 (Dec). CEO Rick Pauls was paid $2.7M of that.

Pay$100 in the stock at the end of FY21 → $213
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Rick PaulsPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Julie Krop, M.D.Chief Medical Officer
FY2025 (Dec)
1 year
Scott KellenChief Financial Officer and Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $2.2M. The CEO of DiaMedica Therapeutics was paid $2.7M, 24% above the median.

  1. 1Fulcrum Therapeutics
  2. 2DiaMedica Therapeutics
  3. 3Gossamer Bio
  4. 4Lineage Cell Therapeutics
  5. 5Galectin Therapeutics
  6. 6Acumen Pharmaceuticals, Inc.Not disclosed
  7. 7Alto NeuroscienceNot disclosed
  8. 8Anavex Life SciencesNot disclosed
  9. 9Annovis Bio, Inc.Not disclosed
  10. 10Applied Therapeutics, Inc.Not disclosed
  11. 11Clene Inc.Not disclosed
  12. 12ImmunicNot disclosed
  13. 13Inozyme Pharma, Inc.Not disclosed
  14. 14MedicinovaNot disclosed
  15. 15Mineralys TherapeuticsNot disclosed
  16. 16Ovid Therapeutics IncNot disclosed
  17. 17PepGen Inc.Not disclosed
  18. 18Tourmaline Bio, Inc.Not disclosed
  19. 19Vigil Neuroscience, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.